Those from patients with SpA and RA exhibited a significantly higher response to CXCL9 compared with HD (Figure 1A), whereas the four cohorts showed a comparable chemotaxis to CXCL10, CXCL11, and CXCL12 (Figure 1B–D). This evidence concerns the gene CXCL9 and rheumatoid arthritis.